Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease
Phase 3
Completed
- Conditions
- chronic kidney diseaseinflammation1001842410038430
- Registration Number
- NL-OMON29938
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
CKD, stage 4 (GFR <30/min), predialysis
Exclusion Criteria
heart failure (NIHA 3 or 4), elevated liver enzymes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary aim of this study will be to determine the effect of rosiglitazone<br /><br>on intima media thickness and calcification</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary end points are the effects on the lipid profile, insulin<br /><br>resistance, blood pressure and inflammation. The drug safety profile is<br /><br>monitored by liver function parameters and weight changes and other adverse<br /><br>events.</p><br>